Effects of treatment with pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet

Teresa Delmoral, Ronald N. Goldberg, Javier Urbon, Cleide Suguihara, Octavio V. Martinez, Joan Stein-Streilein, William J Feuer, Eduardo Bancalari

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Pentoxifylline (PTXF) is a methylxanthine derivative which modifies leukocyte function and inhibits tumor necrosis factor (TNF)-α release. As TNF-α is considered a proximal mediator in the cascade leading to septic shock, we evaluated the ability of PTXF to attenuate the cardiovascular manifestations of sepsis secondary to an infusion of group B β-hemolytic streptococci (GBS). Fifteen anesthetized, mechanically ventilated piglets (weight, 2815 ± 552 g) were randomly assigned to a treatment group which received a continuous infusion of PTXF (5 mg/kg/h) beginning 30 min after GBS (7.5 x 108 colony-forming units/kg/min) administration was started or to a control group which received GBS plus saline as placebo. Comparison of the hemodynamic measurements and arterial blood gases over the first 120 min of bacterial infusion for treatment and control groups revealed the following statistically significant differences (120-min values presented): cardiac output was significantly higher in the PTXF group (0.159 ± 0.035 versus 0.09 ± 0.026 L/kg/min; p < 0.05) as was stroke volume (0.54 ± 0.11 versus 0.27 ± 0.126 mL/kg/beat; p < 0.01). Pulmonary and systemic vascular resistances remained lower in the PTXF-treated animals (167 ± 45 versus 233 ± 69 mm Hg/L/kg/min; p < 0.03) and (427 ± 162 versus 828 ± 426 mm Hg/L/kg/min; p < 0.03, respectively). Median survival time was significantly longer in the PTXF group (180 versus 120 min; p < 0.05). In an additional group of animals, PTXF administration before GBS infusion revealed no attenuation in the rise of TNF-α, accompanying sepsis. These data demonstrate that treatment with PTXF may ameliorate some of the deleterious hemodynamic manifestations of GBS sepsis and result in improved survival in a young animal model without significantly modifying plasma TNF-α levels.

Original languageEnglish
Pages (from-to)469-474
Number of pages6
JournalPediatric Research
Volume40
Issue number3
StatePublished - Sep 1 1996

Fingerprint

Pentoxifylline
Sepsis
Streptococcus agalactiae
Tumor Necrosis Factor-alpha
Therapeutics
Vascular Resistance
Hemodynamics
Control Groups
Septic Shock
Cardiac Output
Stroke Volume
Leukocytes
Stem Cells
Animal Models
Gases
Placebos
Weights and Measures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Effects of treatment with pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet. / Delmoral, Teresa; Goldberg, Ronald N.; Urbon, Javier; Suguihara, Cleide; Martinez, Octavio V.; Stein-Streilein, Joan; Feuer, William J; Bancalari, Eduardo.

In: Pediatric Research, Vol. 40, No. 3, 01.09.1996, p. 469-474.

Research output: Contribution to journalArticle

Delmoral, Teresa ; Goldberg, Ronald N. ; Urbon, Javier ; Suguihara, Cleide ; Martinez, Octavio V. ; Stein-Streilein, Joan ; Feuer, William J ; Bancalari, Eduardo. / Effects of treatment with pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet. In: Pediatric Research. 1996 ; Vol. 40, No. 3. pp. 469-474.
@article{fe3cdabfd05d48608ef50c3767193ec4,
title = "Effects of treatment with pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet",
abstract = "Pentoxifylline (PTXF) is a methylxanthine derivative which modifies leukocyte function and inhibits tumor necrosis factor (TNF)-α release. As TNF-α is considered a proximal mediator in the cascade leading to septic shock, we evaluated the ability of PTXF to attenuate the cardiovascular manifestations of sepsis secondary to an infusion of group B β-hemolytic streptococci (GBS). Fifteen anesthetized, mechanically ventilated piglets (weight, 2815 ± 552 g) were randomly assigned to a treatment group which received a continuous infusion of PTXF (5 mg/kg/h) beginning 30 min after GBS (7.5 x 108 colony-forming units/kg/min) administration was started or to a control group which received GBS plus saline as placebo. Comparison of the hemodynamic measurements and arterial blood gases over the first 120 min of bacterial infusion for treatment and control groups revealed the following statistically significant differences (120-min values presented): cardiac output was significantly higher in the PTXF group (0.159 ± 0.035 versus 0.09 ± 0.026 L/kg/min; p < 0.05) as was stroke volume (0.54 ± 0.11 versus 0.27 ± 0.126 mL/kg/beat; p < 0.01). Pulmonary and systemic vascular resistances remained lower in the PTXF-treated animals (167 ± 45 versus 233 ± 69 mm Hg/L/kg/min; p < 0.03) and (427 ± 162 versus 828 ± 426 mm Hg/L/kg/min; p < 0.03, respectively). Median survival time was significantly longer in the PTXF group (180 versus 120 min; p < 0.05). In an additional group of animals, PTXF administration before GBS infusion revealed no attenuation in the rise of TNF-α, accompanying sepsis. These data demonstrate that treatment with PTXF may ameliorate some of the deleterious hemodynamic manifestations of GBS sepsis and result in improved survival in a young animal model without significantly modifying plasma TNF-α levels.",
author = "Teresa Delmoral and Goldberg, {Ronald N.} and Javier Urbon and Cleide Suguihara and Martinez, {Octavio V.} and Joan Stein-Streilein and Feuer, {William J} and Eduardo Bancalari",
year = "1996",
month = "9",
day = "1",
language = "English",
volume = "40",
pages = "469--474",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of treatment with pentoxifylline on the cardiovascular manifestations of group B streptococcal sepsis in the piglet

AU - Delmoral, Teresa

AU - Goldberg, Ronald N.

AU - Urbon, Javier

AU - Suguihara, Cleide

AU - Martinez, Octavio V.

AU - Stein-Streilein, Joan

AU - Feuer, William J

AU - Bancalari, Eduardo

PY - 1996/9/1

Y1 - 1996/9/1

N2 - Pentoxifylline (PTXF) is a methylxanthine derivative which modifies leukocyte function and inhibits tumor necrosis factor (TNF)-α release. As TNF-α is considered a proximal mediator in the cascade leading to septic shock, we evaluated the ability of PTXF to attenuate the cardiovascular manifestations of sepsis secondary to an infusion of group B β-hemolytic streptococci (GBS). Fifteen anesthetized, mechanically ventilated piglets (weight, 2815 ± 552 g) were randomly assigned to a treatment group which received a continuous infusion of PTXF (5 mg/kg/h) beginning 30 min after GBS (7.5 x 108 colony-forming units/kg/min) administration was started or to a control group which received GBS plus saline as placebo. Comparison of the hemodynamic measurements and arterial blood gases over the first 120 min of bacterial infusion for treatment and control groups revealed the following statistically significant differences (120-min values presented): cardiac output was significantly higher in the PTXF group (0.159 ± 0.035 versus 0.09 ± 0.026 L/kg/min; p < 0.05) as was stroke volume (0.54 ± 0.11 versus 0.27 ± 0.126 mL/kg/beat; p < 0.01). Pulmonary and systemic vascular resistances remained lower in the PTXF-treated animals (167 ± 45 versus 233 ± 69 mm Hg/L/kg/min; p < 0.03) and (427 ± 162 versus 828 ± 426 mm Hg/L/kg/min; p < 0.03, respectively). Median survival time was significantly longer in the PTXF group (180 versus 120 min; p < 0.05). In an additional group of animals, PTXF administration before GBS infusion revealed no attenuation in the rise of TNF-α, accompanying sepsis. These data demonstrate that treatment with PTXF may ameliorate some of the deleterious hemodynamic manifestations of GBS sepsis and result in improved survival in a young animal model without significantly modifying plasma TNF-α levels.

AB - Pentoxifylline (PTXF) is a methylxanthine derivative which modifies leukocyte function and inhibits tumor necrosis factor (TNF)-α release. As TNF-α is considered a proximal mediator in the cascade leading to septic shock, we evaluated the ability of PTXF to attenuate the cardiovascular manifestations of sepsis secondary to an infusion of group B β-hemolytic streptococci (GBS). Fifteen anesthetized, mechanically ventilated piglets (weight, 2815 ± 552 g) were randomly assigned to a treatment group which received a continuous infusion of PTXF (5 mg/kg/h) beginning 30 min after GBS (7.5 x 108 colony-forming units/kg/min) administration was started or to a control group which received GBS plus saline as placebo. Comparison of the hemodynamic measurements and arterial blood gases over the first 120 min of bacterial infusion for treatment and control groups revealed the following statistically significant differences (120-min values presented): cardiac output was significantly higher in the PTXF group (0.159 ± 0.035 versus 0.09 ± 0.026 L/kg/min; p < 0.05) as was stroke volume (0.54 ± 0.11 versus 0.27 ± 0.126 mL/kg/beat; p < 0.01). Pulmonary and systemic vascular resistances remained lower in the PTXF-treated animals (167 ± 45 versus 233 ± 69 mm Hg/L/kg/min; p < 0.03) and (427 ± 162 versus 828 ± 426 mm Hg/L/kg/min; p < 0.03, respectively). Median survival time was significantly longer in the PTXF group (180 versus 120 min; p < 0.05). In an additional group of animals, PTXF administration before GBS infusion revealed no attenuation in the rise of TNF-α, accompanying sepsis. These data demonstrate that treatment with PTXF may ameliorate some of the deleterious hemodynamic manifestations of GBS sepsis and result in improved survival in a young animal model without significantly modifying plasma TNF-α levels.

UR - http://www.scopus.com/inward/record.url?scp=0029811746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029811746&partnerID=8YFLogxK

M3 - Article

C2 - 8865286

AN - SCOPUS:0029811746

VL - 40

SP - 469

EP - 474

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 3

ER -